Company Overview and News
Snap-on Inc. SNA said Thursday that first-quarter net income rose 15%, in part due to the tax overhaul in the U.S. The Wisconsin-based maker of automotive tools, diagnostic equipment, and software earned a quarterly profit of $163 million, or $2.82 a share, compared with $141.6 million, or $2.39 a share, for the same period a year earlier.
CALGARY, Alberta, April 18, 2018 (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (TSX:CVE) (NYSE:CVE) will release its first quarter 2018 results on Wednesday, April 25, 2018. The news release will provide consolidated first quarter operating and financial information. Financial statements will be available on the company’s website, cenovus.com.
Surging U.S. oil supplies may soon struggle to find a buyer, and Morgan Stanley believes that could create winners in the stock and commodity markets.
Yet the stock tanked several times last year on market doubts about Canadian oil industry challenges and the acquisition.
The company announced Sunday that it is suspending non-essential activities and related spending for the Trans Mountain pipeline expansion, casting a cloud over the future of the $7.4-billion project.
Continuing with the biggest movers in the energy sector, we’ll now look at the top gainers from the US integrated energy sector for the week starting April 2.
April 5 (Reuters) - Canada’s main stock index rose more than 1 percent on Thursday, led by a surge in energy stocks and rising confidence that NAFTA talks will result in a positive outcome.
April 5 (Reuters) - Canadian oil and gas producer Cenovus Energy Inc said on Thursday it named Jon McKenzie chief financial officer, bringing in an industry veteran who most recently helped rival Husky Energy Inc rein in costs and strengthen its finances.
The stock price is roughly 5 times the funds flow when considering the exchange rate of the Canadian Dollar.
Higher financial flexibility after asset sale and the company is fully financed for the next 24 months.
March 27 (Reuters) - Canadian railway operators see a lucrative opportunity to transport more crude oil to the United States as a rise in output force producers to find new routes to its southern neighbor.
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
(Reuters) - Canadian railway operators see a lucrative opportunity to transport more crude oil to the United States as a rise in output force producers to find new routes to its southern neighbor.
Headquartered in Houston Texas, United States, ConocoPhillips (NYSE:COP) is the world’s biggest independent exploration and production company. Although the company’s financial performance has improved in 2017 and its stock price has risen by more than 20% in the second half of 2017, I firmly believe that it’s better to remain away from COP as its fundamentals are heavily dependent on energy prices.
The shortage of pipelines and rail transportations has disrupted the production schedule of the companies in Western Canada. The companies had to slow down their activity levels due to difficulty in crude transportation. Oil sands companies such as Cenovus Energy Inc. (CVE - Free Report) , Suncor Energy Inc. (SU - Free Report) and Canadian Natural Resources Ltd. (CNQ - Free Report) witnessed a decline in share prices after Cenovus Energy announced a cut in its production at Christina Lake and Foster Creek complexes.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...